Oral CGRP Drug Bests Placebo for Migraine Prevention

Atogepant, an investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist for migraine prevention, led to fewer monthly migraine days in episodic monthly migraine patients, results of a phase IIb/III trial showed here. 

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on print
Share on email
Pain Medicine Journal
Access to this page is restricted to members only! Not a mamber? Join Now!

Ask Us Anything. Anytime.

📝 Fill in your details and we’ll get back to you in no time.
AAPM

American Academy of Pain Medicine